Sign in
Not yet recruitingNo phase

Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders

Key facts

Who runs it
Kangbuk Samsung Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
185 people, planned
Started
15 May 2025
Expected to end
15 Dec 2029
Type of study
Observational, 2 groups
Treatments tested
  • Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI
Record updated
30 April 2025

Who can take part

Age
19 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (4)Hide the full registry criteria

Who can take part

  • Anxiety Behavior Group; Adults aged 19-60 years; Diagnosed with an anxiety disorder based on DSM-5 diagnostic criteria, evaluated by a board-certified psychiatrist; Individuals who fully understand the study's purpose and process and provide informed consent
  • Healthy Control Group; Adults aged 19-60 years; Individuals who report no psychiatric symptoms and are not taking any psychotropic medications; Individuals who fully understand the study's purpose and process and provide informed consent

Who cannot take part

  • Anxiety Behavior Group; Individuals unable to read the consent form; Individuals with difficulty using virtual reality devices; Individuals with a history of epileptic seizures, brain injuries, or neurological disorders; Individuals with severe physical illnesses (e.g., cancer, tuberculosis, severe cardiovascular diseases); Individuals with substance or alcohol use disorders; Individuals with pacemakers or implanted metallic devices; Pregnant individuals or those in vulnerable environments, such as institutional employees
  • Healthy Control Group; Exclusion criteria for the Anxiety behavior group apply; Additionally, individuals with any current or past psychiatric disorders are excluded

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Panic disorder

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to build a comprehensive brain and behavioral dataset on anxiety disorders and identify clinical factors related to treatment response and prognosis in patients with anxiety disorders. By conducting an integrated analysis of clinical features (phenotypes), comorbid conditions, virtual reality (VR)-based behavioral data, electroencephalogram (EEG) data, and MRI-based data in patients undergoing treatment for anxiety disorders and healthy controls, this study aims to enhance the understanding of the pathophysiology of anxiety disorders and establish a foundation for precision medicine.

Read full original descriptionShow less

Anxiety disorders significantly impair quality of life by inducing irrational fear and apprehension even in everyday situations. Over the past few years, the prevalence of anxiety disorders and associated medical expenses have surged, escalating the societal and economic burden. However, the current diagnostic system, DSM-5, relies on symptom-based approaches, which often lead to heterogeneity within the same diagnostic category. This limitation hinders the accurate prediction of treatment response and the design of optimal therapeutic strategies. To address these issues, the U.S. National Institute of Mental Health (NIMH) proposed the Research Domain Criteria (RDoC). RDoC is a multidimensional framework that integrates behavioral, psychological, and neurological data to facilitate the development of treatment strategies rooted in pathophysiology. Nonetheless, the acquisition of objective and reliable assessment data remains a challenge due to the inherent characteristics of mental disorders.

Virtual reality (VR) technology has emerged as a promising solution to overcome these limitations. VR enables the creation of immersive 3D environments that can elicit anxiety-related behaviors and precisely evaluate them in controlled settings. It also allows data collection in scenarios that closely resemble real-life situations while offering advantages such as repeatability and ease of use. Combining behavioral data collected in VR environments with EEG data can provide a more detailed understanding of the neurophysiological representations underlying anxiety behaviors. EEG, as a biomarker reflecting neural activity in real time, facilitates intuitive and effective analyses. Moreover, MRI-based brain imaging plays a critical role in identifying structural and functional connectivity differences between anxiety disorder patients and healthy controls. It offers crucial insights into the biomarkers that predict treatment outcomes and prognosis.

By integrating these data, this study seeks to uncover the key factors influencing treatment response and prognosis in patients with anxiety disorders.

The 2 groups in the trial

  • Anxiety Behavior Group

    Participants diagnosed with an anxiety disorder based on DSM-5 diagnostic criteria, evaluated by a board-certified psychiatrist. The principal investigator, a board-certified psychiatrist, will conduct the following diagnostic assessments and differential diagnoses to screen eligible participants according to the inclusion and exclusion criteria. Anxiety disorders will be diagnosed using the Structured Clinical Interview for DSM-5 Disorders, Clinical Version (SCID-5-CV; First et al., 2016), and other major psychiatric conditions will be ruled out using the Mini International Neuropsychiatric Interview (MINI; Lecrubier et al., 1997). Participants will undergo four visits (initial evaluation, 2-month follow-up, 6-month follow-up, and 12-month follow-up).

    Treatment: Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI

  • Healthy Control Group

    Individuals who report no psychiatric symptoms and are not taking any psychotropic medications. Participants will undergo two visits (initial evaluation and 12-month follow-up).

    Treatment: Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06773585, who can take part
Record updated
30 April 2025